Erlizumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameErlizumab
Drug Alias NamerhuMAb CD18Anti-CD18 monoclonal antibody - Genentech
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionImmunosuppressants
TargetsNot applicable
Therapy Area/IndicationsShockMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech IncPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche LtdGenentech IncPdl Biopharma Inc
Active IndicationsN/A
Inactive IndicationsShockMyocardial Infarction

Other Information

ATC CodeN/A
Related LinksN/A